

**IN THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-36. (Canceled)

37. (Previously presented) An isolated polypeptide comprising SEQ ID NO:4, wherein said polypeptide binds at least one of human IL-13 and human IL-4.

38. (Currently amended) An isolated polypeptide comprising a ~~part~~ or fragment of SEQ ID NO:4.

39. (Previously presented) The isolated polypeptide of Claim 38 comprising amino acids 26 to 426 of SEQ ID NO:4.

40. (Previously presented) The isolated polypeptide of Claim 38 comprising amino acids 26 to 345 of SEQ ID NO:4.

41. (Currently amended) The isolated polypeptide of claim ~~30~~38 or 40 in soluble form.

42. (Previously presented) The isolated polypeptide of claim 37 wherein said polypeptide is glycosylated.

43. (Previously presented) The isolated polypeptide of claim 37 wherein said polypeptide is unglycosylated.

44. (Previously presented) The isolated polypeptide of Claims 37-40 in recombinant form.

45. (Previously presented) The isolated polypeptide of any one of claims 38-40 in mature form.

46. (Canceled)

47. (Previously presented) A composition comprising the isolated polypeptide of Claim 37 and a pharmaceutically acceptable carrier.

48. (Previously presented) A composition comprising the isolated polypeptide of Claim 38 and a pharmaceutically acceptable carrier.

49. (Previously presented) A composition comprising the isolated polypeptide of Claim 39 and a pharmaceutically acceptable carrier.

50. (Previously presented) A composition comprising the isolated polypeptide of Claim 40 and a pharmaceutically acceptable carrier.

51. (Canceled)